Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.
- Resource Type
- Authors
- Pantarotto M; Oncology, Champalimaud Foundation, Lisbon, PRT.; Barata R; Lung Unit, Champalimaud Foundation, Lisbon, PRT.; Coelho R; Lung Unit, Champalimaud Foundation, Lisbon, PRT.; Sousa V; Dermatology, Champalimaud Foundation, Lisbon, PRT.; Carvalheiro C; Lung Unit, Champalimaud Foundation, Lisbon, PRT.; Rolim I; Lung Unit, Champalimaud Foundation, Lisbon, PRT.; Garrido P; Lung Unit, Champalimaud Foundation, Lisbon, PRT.; GIl N; Lung Unit, Champalimaud Foundation, Lisbon, PRT.; Duarte-Ramos F; Faculty of Pharmacy, University of Lisbon, Lisbon, PRT.; Tonin FS; Health & Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PRT.
- Source
- Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
- Subject
- Language
- English
- ISSN
- 2168-8184
[This corrects the article DOI: 10.7759/cureus.26729.].
Competing Interests: No competing interests declared.
(Copyright © 2023, Pantarotto et al.)